Amlodipine/valsartan - Wiki slovník

Amlodipine/valsartan
Combination of
Amlodipine	Calcium channel blocker
Valsartan	Angiotensin II receptor antagonist
Clinical data
Trade names	Exforge
AHFS/Drugs.com	Professional Drug Facts
License data	EU EMA: by INN; US DailyMed: Amlodipine_and_valsartan;
Pregnancy; category	AU: D; ;
Routes of; administration	By mouth
ATC code	C09DB01 (WHO) ;
Legal status
Legal status	US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	1190398-97-0;
PubChem CID	11354874;
ChemSpider	13092186 ;
KEGG	D09745 ; with HCTZ: D10286 ;
CompTox Dashboard (EPA)	DTXSID10180185 ;
	(verify)

Amlodipine/valsartan, sold under the brand name Exforge among others, is a blood pressure lowering combination drug. It contains amlodipine, as the besilate, a dihydropyridine-type calcium channel blocker, and valsartan, an angiotensin II receptor antagonist.^[3] This combination is usually well tolerated and effective for the reduction of blood pressure.^[4]

The combination was approved for medical use in the United States in June 2007.^[5]

The combination is also available with included hydrochlorothiazide (Exforge HCT), for people who need a three-drug regimen to manage their blood pressure.^[6]^[7] It was approved for medical use in the United States in April 2009.^[8]

References

^ "Amlodipine / valsartan (Exforge) Use During Pregnancy". Drugs.com. 11 July 2019. Retrieved 13 February 2020.
^ "Exforge- amlodipine besylate and valsartan tablet, film coated". DailyMed. 12 June 2019. Retrieved 12 February 2020.
^ "Valsartan Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
^ Eckert S, Freytag SB, Müller A, Klebs SH (September 2013). "Meta-analysis of three observational studies of amlodipine/valsartan in hypertensive patients with additional risk factors". Blood Pressure. 22 (sup1): 11–21. doi:10.3109/08037051.2013.793891. PMID 23713686. S2CID 25814898.
^ "Drug Approval Package: Exforge (amlodipine and valsartan) NDA #021990". U.S. Food and Drug Administration (FDA). 3 October 2008. Retrieved 19 September 2021.
^ "Exforge HCT- amlodipine valsartan and hydrochlorothiazide tablet, film coated". DailyMed. Retrieved 12 February 2020.
^ "Amlodipine, Valsartan, and Hydrochlorothiazide". Drugs.com.
^ "Drug Approval Package: Exforge HCT (Amlodipine, Valsartan, Hydrochlorothiazide) Tablets NDA #022314". U.S. Food and Drug Administration (FDA). 2 September 2009. Retrieved 19 September 2021.

External links

"Amlodipine mixture with valsartan". Drug Information Portal. U.S. National Library of Medicine.
"Amlodipine besylate mixture with hydrochlorothiazide and valsartan". Drug Information Portal. U.S. National Library of Medicine.

This antihypertensive-related article is a stub. You can help Wikipedia by expanding it.

Zdroj:https://en.wikipedia.org?pojem=Amlodipine/valsartan
>Text je dostupný pod licencí Creative Commons Uveďte autora – Zachovejte licenci, případně za dalších podmínek. Podrobnosti naleznete na stránce Podmínky užití.

[Drugs.com_pregnancy-1] "Amlodipine / valsartan (Exforge) Use During Pregnancy". Drugs.com. 11 July 2019. Retrieved 13 February 2020.

[Exforge_FDA_label-2] "Exforge- amlodipine besylate and valsartan tablet, film coated". DailyMed. 12 June 2019. Retrieved 12 February 2020.

[AHFS2019-3] "Valsartan Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.

[EckertFreytag2013-4] Eckert S, Freytag SB, Müller A, Klebs SH (September 2013). "Meta-analysis of three observational studies of amlodipine/valsartan in hypertensive patients with additional risk factors". Blood Pressure. 22 (sup1): 11–21. doi:10.3109/08037051.2013.793891. PMID 23713686. S2CID 25814898.

[5] "Drug Approval Package: Exforge (amlodipine and valsartan) NDA #021990". U.S. Food and Drug Administration (FDA). 3 October 2008. Retrieved 19 September 2021.

[6] "Exforge HCT- amlodipine valsartan and hydrochlorothiazide tablet, film coated". DailyMed. Retrieved 12 February 2020.

[7] "Amlodipine, Valsartan, and Hydrochlorothiazide". Drugs.com.

[8] "Drug Approval Package: Exforge HCT (Amlodipine, Valsartan, Hydrochlorothiazide) Tablets NDA #022314". U.S. Food and Drug Administration (FDA). 2 September 2009. Retrieved 19 September 2021.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

v t e Antihypertensive drugs acting on the renin–angiotensin system (C09)
ACE inhibitors ("-pril")	Sulfhydryl-containing: Captopril Rentiapril Zofenopril Dicarboxylate-containing: Enalapril^# Benazepril Cilazapril Delapril Imidapril Lisinopril (+amlodipine, +HCT) Moexipril Perindopril (+indapamide) Quinapril (+HCT) Ramipril Spirapril Temocapril Trandolapril Phosphonate-containing: Ceronapril Fosinopril (+HCT) Other/ungrouped: Alacepril
AIIRAs ("-sartan")	Azilsartan Candesartan Eprosartan Fimasartan Irbesartan (+HCT) Losartan (+HCT) Olmesartan (+amlodipine, +amlodipine and HCT, +HCT) Tasosartan^§ Telmisartan (+amlodipine, +HCT) Valsartan (+amlodipine, +amlodipine and HCT, +HCT, +nebivolol)
Renin inhibitors ("-kiren")	Aliskiren (+amlodipine, +HCT, +amlodipine and HCT) Remikiren^§
Dual ACE/NEP inhibitors	Gemopatrilat Ilepatril Omapatrilat Sampatrilat
Neprilysin inhibitors	Sacubitril (+valsartan)
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III